Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? - Cancer Treatment Reviews
Erbitux Mechanism of Action
Table 3 from A Novel Anti-EGFRMonoclonal Antibody , Cetuximab(Erbitux R ) | Semantic Scholar
ERBITUX (cetuximab) for Head and Neck Cancer and Colorectal Cancer - Cancer Therapy Advisor
Panitumumab - Dubois - 2009 - British Journal of Clinical Pharmacology - Wiley Online Library
Targeted biotherapy in metastatic colorectal carcinoma: Current practice - ScienceDirect
2: Mode of action of Cetuximab. The epidermal growth factor receptor... | Download Scientific Diagram
Cetuximab | Nature Reviews Drug Discovery
Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies | Journal of Experimental & Clinical Cancer Research | Full Text
Frontiers | Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors | Oncology
Cetuximab-Triptolide Conjugate Suppresses the Growth of EGFR-Overexpressing Lung Cancers through Targeting RNA Polymerase II: Molecular Therapy - Oncolytics
First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab. - Abstract - Europe PMC
Predictive Biomarkers for Monoclonal Antibody Therapies Targeting EGFR ( Cetuximab, Panitumumab) in the Treatment of Metastatic Colorectal Cancer | IntechOpen
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer
SMPDB
Cetuximab - Classes of Monoclonal Antibodies: Endothelial Growth Factor Receptor (EGFR) Inhibitors
Frontiers | The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells | Oncology
The Influence of K-ras Exon 2 Mutations on Outcomes - ppt download
Gold nanoparticles conjugated to Cetuximab antibody against cancer - UABDivulga Barcelona Research & Innovation
Clinical development of targeted and immune based anti-cancer therapies | Journal of Experimental & Clinical Cancer Research | Full Text
Cancers | Free Full-Text | Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib
Anti-EGFR Mechanism of Action: Antitumor Effect and Underlying Cause of Adverse Events
